Cargando…

Evaluation and consequences of heterogeneity in the circulating tumor cell compartment

A growing understanding of the molecular biology of cancer and the identification of specific aberrations driving cancer evolution have led to the development of various targeted agents. Therapeutic decisions concerning these drugs are often guided by single biopsies of the primary tumor. Yet, it is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brouwer, Anja, De Laere, Bram, Peeters, Dieter, Peeters, Marc, Salgado, Roberto, Dirix, Luc, Van Laere, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217044/ https://www.ncbi.nlm.nih.gov/pubmed/26980749 http://dx.doi.org/10.18632/oncotarget.8015

Ejemplares similares

HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques
por: Brouwer, Anja, et al.
Publicado: (2019)

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
por: Dirix, Luc, et al.
Publicado: (2022)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
por: Oeyen, Steffi, et al.
Publicado: (2020)

Molecular profiles to biology and pathways: a systems biology approach
por: Van Laere, Steven, et al.
Publicado: (2016)

Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer
por: Dirix, Luc Y., et al.
Publicado: (2022)

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis
por: Rothé, Françoise, et al.
Publicado: (2022)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals Krüppel-like factor 9 as a potential suppressor of invasive growth in breast cancer
por: Limame, Ridha, et al.
Publicado: (2013)

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers
por: van Schooneveld, Eleni, et al.
Publicado: (2012)

Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma
por: Philippron, Annouck, et al.
Publicado: (2021)

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting
por: Peeters, D J E, et al.
Publicado: (2013)

Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer
por: Van der Auwera, I, et al.
Publicado: (2010)

Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma
por: Trinh, Xuan Bich, et al.
Publicado: (2011)

Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth
por: Vermeulen, P B, et al.
Publicado: (2009)

Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management
por: van Schooneveld, Eleni, et al.
Publicado: (2015)

Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
por: Baay, Marc, et al.
Publicado: (2011)

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients
por: Van der Auwera, I, et al.
Publicado: (2009)

Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer
por: Steenbrugge, Jonas, et al.
Publicado: (2019)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

The interaction between ER and NFκB in resistance to endocrine therapy
por: Sas, Leen, et al.
Publicado: (2012)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
por: De Laere, Bram, et al.
Publicado: (2021)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients
por: Van der Auwera, Ilse, et al.
Publicado: (2010)

A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
por: Mercier, Carole, et al.
Publicado: (2018)

Distributional consequences of including survivor costs in economic evaluations
por: Kellerborg, Klas, et al.
Publicado: (2021)

Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorization
por: Renaud, Gabriel, et al.
Publicado: (2022)

Monitoring Circulation During Transition in Extreme Low Gestational Age Newborns: What’s on the Horizon?
por: Van Laere, David, et al.
Publicado: (2018)

Study Assessing the Quality of Quantification of Estrogen Receptor Protein Expression by Immunohistochemistry and Gene Expression in Breast Cancer
por: Leen, Sas, et al.
Publicado: (2014)

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer
por: Rolfo, Christian, et al.
Publicado: (2018)

Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype
por: Van der Auwera, I, et al.
Publicado: (2010)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

Understanding tumor heterogeneity as functional compartments - superorganisms revisited
por: Grunewald, Thomas GP, et al.
Publicado: (2011)

Identification of Macrophage Genotype and Key Biological Pathways in Circulating Angiogenic Cell Transcriptome
por: Everaert, Bert R., et al.
Publicado: (2019)

Precision of image-guided spinal stereotactic ablative radiotherapy and impact of positioning variables
por: Billiet, Charlotte, et al.
Publicado: (2022)

A Core Invasiveness Gene Signature Reflects Epithelial-to-Mesenchymal Transition but Not Metastatic Potential in Breast Cancer Cell Lines and Tissue Samples
por: Marsan, Melike, et al.
Publicado: (2014)

Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations
por: Bertucci, François, et al.
Publicado: (2020)

Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination
por: Van der Auwera, Ilse, et al.
Publicado: (2010)

Breast tumor heterogeneity: causes and consequences
por: Polyak, K, et al.
Publicado: (2009)

Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target
por: Richard, François, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7404a1saijqf5v1hvmpge7gv1r